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A
n exciting era is upon us in terms of new
therapies for patients with diabetes, obesity,
and metabolic syndrome. One such advance is
the ability to selectively manipulate tissue lev-
els of glucocorticoids through targeted inhibition of corti-
sol metabolic pathways. Perhaps the best paradigm for
metabolic syndrome comes from patients with Cushing’s
syndrome, with their characteristic central obesity, glu-
cose intolerance, hypertension, and premature cardio-
vascular mortality. Although circulating cortisol
concentrations are invariably normal in patients with
obesity and metabolic syndrome (1), in vitro, in vivo, and
clinical studies over the last decade have collectively
shown the importance of local generation of cortisol, via
11-hydroxysteroid dehydrogenase type 1 (11-HSD1) in
liver and fat, in mediating many facets of the metabolic
syndrome (2). Major pharmaceutical companies are now
engaged; over 50 patents have been issued detailing com-
pounds and strategies for selective 11-HSD1 inhibition.
Preclinical animal studies have shown proof of concept,
with improved glucose tolerance and weight reduction
reported in many diabetic and obese mouse models
treated with 11-HSD1 inhibitors (3–6). Phase I and II
clinical data reported at the American Diabetes Associa-
tion’s Scientiﬁc Sessions in June 2008 were equally encour-
aging (7).
11-HSD1 is a bidirectional enzyme that interconverts
hormonally inactive cortisone to cortisol. Unlike cortisol,
cortisone is not synthesized within the adrenal gland; its
circulating pool of 80 nmol/l is largely dependent on
dehydrogenase activity (cortisol to cortisone) from the
related isozyme 11-HSD2, expressed in kidney and gut.
Nevertheless, the reductase activity of 11-HSD1 can
regenerate cortisol in tissues with high enzyme expres-
sion, predominantly liver and fat.
The autocrine consequences of this are clear: in the
liver, facilitating hepatic glucose output through stimu-
lated gluconeogenesis, and in adipose tissue, stimulating
adipogenesis and lipolysis with release of free fatty acids.
But what is the overall contribution, if any, of this gener-
ation of cortisol from liver and fat to circulating concen-
trations? Importantly, what might be the additional effect
of 11-HSD1 in omental fat delivering excess cortisol to
the liver via the portal vein?
In this issue of Diabetes, Stimson et al. (8) and Basu et
al. (9) have used stable cortisol isotopes in detailed
clinical integrative physiological studies to evaluate the
relative contribution of liver versus fat in generating
cortisol via the 11-HSD ﬂux. Deuterated D4 cortisol is
infused, which, when converted by 11-HSD2, yields D3
cortisone. The subsequent appearance of D3 cortisol ex-
clusively reﬂects 11-HSD1 reductase activity. Selective
catheterization of hepatic vein, portal vein, and abdominal
vascular beds conﬁrms that the liver is a major cortisol
producer; the absolute values differ markedly from study
to study, and some results seen are incompatible with
normal daily cortisol secretion rates. For example, Basu et
al. report a hepatic cortisol production rate of 23 g/min,
which equates to 33 mg/day, and Stimson et al. report 18
mg/day; both are greatly in excess of the established daily
cortisol production rate of 10 mg/day (10). Stimson et al.
also show that subcutaneous fat can generate cortisol, and
this may explain in part the increased cortisol secretion
rates documented in obesity. Both studies, however, are
quite clear in showing no apparent release of cortisol from
the viscera: all of the increased cortisol production in the
splanchnic circulation reﬂects hepatic and not visceral
production. The data conﬁrm earlier canine studies per-
formed in the laboratory of R.A. Rizza (11) but seem to
contradict earlier studies by Walker and colleagues (12)
that suggested that up to two-thirds of splanchnic cortisol
production might originate from the viscera.
There are some additional caveats. Such invasive stud-
ies are not possible on healthy volunteers. Patients studied
had either severe obesity and were undergoing bariatric
surgery or had severe liver disease and were undergoing
portal venous shunting; both scenarios have been shown
to signiﬁcantly alter cortisol secretion and metabolism.
Furthermore, the catheterization procedures do not spe-
ciﬁcally sample omental fat but reﬂect drainage into the
whole portal vein that may cause some dilution from other
visceral tissues. Of particular relevance might be the gut,
which expresses abundant amounts of 11-HSD2 that may
contribute to increased portal vein cortisone concentra-
tions. These issues aside, it seems unlikely that visceral fat
contributes a signiﬁcant delivery of cortisol to the liver.
Do these ﬁndings alter our desire to inhibit 11-HSD1 in
liver and fat in patients with metabolic syndrome? Proba-
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14 DIABETES, VOL. 58, JANUARY 2009bly not. Undoubtedly, the major immediate effect of 11-
HSD1 inhibition in patients with diabetes will relate to
reduced glucocorticoid-mediated hepatic glucose output.
However, the longer-term beneﬁcial effects of blocking the
autocrine actions of cortisol in omental adipose tissue
should not be dismissed. This may not impact on exposure
of the liver to portal vein steroids, but the reduction in
adipogenesis will improve body composition and poten-
tially improve other cardiovascular risk factors such as
dyslipidemia and hypertension.
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